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Purpose: Concerns have been raised that modern intensity modulated radiotherapy
(IMRT) may be associated with increased second primary cancer risks (SPC) compared to
previous three-dimensional conformal radiation techniques (3DCRT), due to increased low
dose volumes and more out-of-field ionizing dose to peripheral tissue further away from
the target. We assessed the impact of treatment technique on SPC risks in a cohort of
prostate cancer (PCa) survivors.
Material and Methods: The study cohort comprised 1,561 PCa survivors aged 50–79
years at time of radiotherapy, treated between 2006–2013 (N=707 IMRT, N=854 3DCRT).
Treatment details were extracted from radiotherapy systems and merged with longitudinal
data of the Netherlands Cancer Registry to identify SPCs. Primary endpoint was the
development of a solid SPC (excluding skin cancer) in peripheral anatomical regions, i.e.
non-pelvic. Applied latency period was 12 months. SPC rates in the IMRT cohort (total
cohort and age subgroups) were compared to 1) the 3DCRT cohort by calculating Sub-
Hazard Ratios (sHR) using a competing risk model, and 2) to the general male population
by calculating Standardized Incidence Ratios (SIR). Models were adjusted for calendar
period and age.
Results:Median follow-up was 8.0 years (accumulated 11,664 person-years at-risk) with
159 cases developing ≥1 non-pelvic SPC. For IMRT vs 3DCRTwe observed a significantly
(p=0.03) increased risk (sHR=1.56, 95% Confidence Interval (CI) 1.03–2.36,
corresponding estimated excess absolute risk (EAR) of +7 cases per 10,000 person-
years). At explorative analysis, IMRT was in particular associated with increased risks
within the subgroup of active smokers (sHR 2.94, p=0.01). Within the age subgroups 50–
69 and 70–79 years, the sHR for non-pelvic SPC was 3.27 (p=0.001) and 0.96 (p=0.9),
respectively. For pelvic SPC no increase was observed (sHR=0.8, p=0.4). Compared to
the general population, IMRT was associated with significantly increased risks for non-
pelvic SPC in the 50–69 year age group (SIR=1.90, p<0.05) but not in the 70–79 years
group (SIR=1.08).November 2020 | Volume 10 | Article 6051191
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Frontiers in Oncology | www.frontiersin.orgConclusion: IMRT is associated with increased SPC risks for subjects who are relatively
young at time of treatment. Additional research on aspects of IMRT that may cause this
effect is essential to minimize risks for future patients receiving modern radiotherapy.Keywords: prostate cancer, second primary cancer, survivorship, intensity-modulated radiotherapy, three-
dimensional conformal radiotherapyINTRODUCTION
Radiotherapy (RT) is an important treatment modality in cancer
treatment and intensity-modulated radiotherapy (IMRT) is one
of its most important recent developments. It is characterized by
a highly conformal dose delivery to the tumor and hence
improved sparing of normal tissue. This requires a longer
beam-on time and results in larger low dose volumes and
more out-of-field ionizing dose to peripheral healthy tissue
further away from the target (1, 2). It is therefore increasingly
recognized that modern RT might result in excess DNA damage
in peripheral tissues, potentially increasing the risk of SPC,
especially for young patients with favorable survival (3–5). To
date, there are insufficient clinical data to draw firm conclusions
about the impact modern RT has on SPC risks (6, 7).
In the Netherlands and worldwide, the prostate cancer (PCa)
patient population was one of the first groups for whom IMRT was
introduced (8). PCa is one of the most common cancer diagnoses
with a growing population of long-term survivors (9). Many
previous cohort studies in the 3DCRT era have addressed SPC
risks in PCa survivor cohorts. They consistently reported limited
excess SPC risks for mainly bladder and rectal cancer (6, 7, 9, 10).
The impact of IMRT dose distributions on SPC risks is a topical
research question, addressed in many recent model studies,
evaluating risks for different age categories and different IMRT
features. Their conclusions vary from hypothesized limited excess
risks to a two- to threefold increase in radiation-induced SPCs (1, 2,
11). Therefore there is a need for large cohort studies with clinical
data and sufficient follow-up to further address this issue.
Theaimof thepresent studywas toassess the riskofdevelopinga
SPC in a PCa survivor cohort, comparing an IMRT cohort with the
Dutch general population (external reference group) and with a
3DCRT cohort (internal reference group), treated in the same era
and at the same institute for localized PCa. We hypothesized that
IMRT is associated with excess out-of-field (i.e. non-pelvic) SPC
risks due to increased peripheral dose levels.METHODS
Study Design and Participants
This retrospective cohort study consisted of 1,561 PCa survivors,
previously treated with RT for localized PCa at the Erasmus
Medical Center, Rotterdam, The Netherlands between 2006–
2013, aged between ≥50–<80 years at time of treatment. RT was
planned and delivered with either IMRT or 3DCRT. IMRT was
gradually introduced during the period 2007–2010. Exclusion
criteria for this study were the presence of metastatic disease,2
previous RT to pelvis areas and simultaneous treatment for other
tumors. The study protocol was reviewed by the Medical Ethical
Committee of the Erasmus Medical Center (EMC 1812730) and
permission was obtained for retrospective anonymized data
collection, in accordance with local and national regulations.
Radiotherapy Protocol
The prescribed dose to the prostate was 72 Gy or 78 Gy in daily
fractions of 2 Gy; from June 2010 onwards 78 Gy became the
standard prescription dose for intermediate to high-risk disease. The
prescribed dose to the Seminal Vesicles (SVs) varied between 0–78
Gy, depending on the estimated probability of SV involvement and
slightly changing guidelines over time (12, 13). Elective lymph node
irradiation was not applied. IMRT beam arrangements typically
included a 7-field technique and 3DCRT was delivered with a 3-
field technique (two lateral and one anterior-posterior field). The
planning target volume was the prostate (+/− SV) plus 10 mm
margin in case of off-line setup verification, and 5–7 mm in case of
on-line setup verification. A full bladder protocol was applied.
Offline setup verification was performed on bony anatomy during
the first three days and then weekly; online verification was
performed with daily tracking of the prostate position using intra-
prostatic implanted fiducial markers. The image-guidance
procedures were performed with planar megavoltage (MV) portal
imaging, or, for 10 MV IMRT with a combination of planar MV
and planar kilovoltage (kV) imaging. For offline MV imaging,
additional larger pelvic imaging field were applied incidentally,
when the treatment field did not contain sufficient information
for the verification procedure.
Data Collection
Wecollecteddata fromthe electronicpatientfiles andRTsystems at
the Erasmus MC and from the nationwide Netherlands Cancer
Registry (NCR). This included patient and tumor characteristics,
smoking status, adjuvant hormonal therapy prescription, and
details of the RT course. Information regarding SPC diagnosis,
vital status, date of death (if applicable), and date of emigration was
obtained from the NCR. Linkage was performed based on date of
birth and postal code at time of treatment. In six cases no match
could be made. For these patients the SPC and vital status
information was extracted from the electronic patient files. All
cancers in the NCR are coded according to The International
Classification of Disease for Oncology (ICD-O-3), and for this
study were converted to ICD-10.
SPC Endpoints
We defined time at risk for SPC from 1 year after start of RT
onwards. For SIR calculations we used 1 year after diagnosis as aNovember 2020 | Volume 10 | Article 605119
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the NCR database. The following cancer sites were evaluated
(further details in Supplementary File 1): a) all solid malignant
neoplasms (C00–C80) except mesothelioma, skin cancer and
prostate cancer, b) solid pelvic SPCs c) solid non-pelvic SPCs
(primary endpoint), d) solid cancers per anatomic region (pelvis,
thorax, abdomen), and e) solid separate (grouped) cancer sites –
provided that sufficient events were observed.
Statistical Analysis
Standardized incidence ratios (SIRs) were calculated in order to
determine the risk of developing a SPC among PCa survivors in
comparison with the Dutch general population. The SIR was
computed by dividing the observed cancer cases in this study by
the expected cancer cases in the Dutch general population based
on age-, gender-, and calendar specific cancer incidence rates
retrieved from the NCR. For SIR calculations, patients with no
match, patients with <1-year follow-up, and patients diagnosed
with PCa before the year 2005, i.e. with larger interval between first
diagnosis and RT, were excluded (n=13), leaving 1,548 subjects for
analysis. All subsequent SPCs after PCa diagnosis were considered
in this analysis up to December 31st 2019. SIRs were calculated for
all defined SPC endpoints for the IMRT cohort, 3DCRT cohort
and total cohort. Additionally, SIRs were calculated for different
patient age groups (50–69 years and 70–79 years). The SIR
analysis and 95% Confidence Intervals (CI) were calculated
using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
For the comparison of the exposed IMRT cohort versus the
reference 3DCRT cohort, competing risk analysis was carried out
using the Fine and Gray method for estimating relative risk [sub
Hazard Ratios (sHRs)] (14). Only the first SPC after PCa diagnosis
was considered. We adjusted all models for age at RT and calendar
period. Cumulative incidences of SPCs were estimated in the
presence of death and non-solid SPC as competing risk. SPCs
occurring within 3 months of one another were considered as
synchronous and both included in the analysis. Follow-up duration
was defined as time since start RTuntil the date of diagnosis of SPC,
date of death, date of emigration or end offollow-up or end of study
(whichever came first). All patients were censured after 11 years of
follow-up to adjust for differences in maximum follow-up between
the two groups, as IMRT was later introduced. End of study was
December 2019. Significancewas set at p <0.05. The competing risk
analysis was conducted using Stata version 14 (STATA Corp.,
Texas, USA).RESULTS
General
Baseline and treatment-related characteristics are displayed in
Table 1. Out of the 1,561 PCa survivors, 707 received IMRT
and 854 received 3DCRT. Median age at follow-up was 71 years
(IQR 64–74) for the IMRT group and 71 years (IQR 66–75) for the
3DCRT group. As indicated in Table 1, the IMRT cohort differed
significantly from the 3DCRT cohort with respect to most of the
reported characteristics. In particular, they received much moreFrontiers in Oncology | www.frontiersin.org 3often 78 Gy (98 vs 56% in the 3DCRT group). With respect to
treatment, the proportion of IMRT patients receiving adjuvant
hormonal therapy (57 vs 48%) and the proportion with inclusion
of the seminal vesicles (83 vs 77%) was larger as well. Furthermore,
the applied photon beam energy differed, and IMRT patients were
more often treated with an online protocol which involved smaller
safety margins and daily imaging; daily imaging was however not
performed with advanced 3D cone beam imaging but for most
cases with 2D treatment fields (as described in the Methods
section). Distribution of smoking in the IMRT and 3DCRT were
very similar with 18% smoking at time of treatment. Overall
survival of the cohort was 62% (IMRT) and 60% (3DCRT) at 10
years (p=0.8).
During follow-up, 225 survivors developed a solid SPC in the
total cohort with 11,664-person-years, excluding the latency of 1
year calculated from start RT; excluding the latency of 1 year
calculated from date of diagnosis (for the SIR analysis), 233
survivors had developed a solid SPC (Tables 2–4). This results in
an overall crude SPC rate of 19.3 events of a first SPC per 10,000
person-years. In the IMRT cohort (4,738 person-years), 99 solid
SPCs were observed, which is a crude incidence rate of 25.1 SPCs
per 10,000 person-years. In the 3DCRT cohort (126 SPCs in
6,926 person-years) the crude incidence rate was 19.2 SPCs per
10,000-person years (Table 4).
Comparison to the General Population
The estimated SIR (95% confidence interval) for any solid SPCs
(excluding skin, mesothelioma, and prostate) was 0.92 (0.80–
1.04) in the total cohort (Table 2), 1.05 (0.85–1.27) in the IMRT
cohort and 0.83 (0.70–0.99) in the 3DCRT cohort (Table 3). For
non-pelvic tumors the estimated SIR for solid SPCs (excluding
skin, mesothelioma, and prostate) was 1.37 (1.07–1.72) in the
IMRT cohort and 1.09 (0.88–1.33) in the 3DCRT cohort
(Table 3).
Comparison of IMRT With 3DCRT
For the total cohort the adjusted sHR (95% confidence interval)
(IMRT vs 3DCRT) for developing a solid SPC outside the pelvis
was 1.56 (1.03–2.36, p=0.034) (Table 4, Figure 1). For all SPCs
regardless anatomic region, this was 1.23 (0.88–1.76, p=0.220).
For pelvic tumors this was 0.79 (0.41–1.47, p=0.437).
Sensitivity Analysis
We evaluated in a sensitivity analysis whether other treatment-
related factors had an impact as well, since the IMRT and
3DCRT cohort differed with respect to seminal vesicle dose,
prostate dose, adjuvant hormonal treatment prescription, and
using online or offline setup protocol (with different safety
margins). Note that for online imaging, no 3D cone beam CT
was involved (as described in the Methods section). For that
purpose, we added each factor to our baseline multivariable
model for the main endpoint of non-pelvic SPC. Results are
summarized in Supplementary File 2, including estimated sHRs
of these additional factors and the corresponding sHRs for IMRT
vs 3DCRT within each alternative model. It shows that none of
the other treatment factor had an impact, and estimated SHRs
for IMRT vs 3DCRT within each alternative model remainedNovember 2020 | Volume 10 | Article 605119
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repeated our main analysis for the 78 Gy subgroup only, since the
IMRT and 3DCRT group show the largest difference with respect
to this treatment characteristic. As shown in Supplementary File
2, the estimated sHR remained again very similar (1.53 versus
1.56 for the total group). The corresponding p value was 0.055
(IMRT vs 3DCRT, 78 Gy subcohort only).
As described in the following paragraphs, smoking status was
associated with SPC risks, but the distribution of smoking status
was equal between the RT technique groups.
Age Subgroups
In PCa survivors aged 50–≤ 69 years at time of treatment, IMRT
was associated with a significant excess SPC risk compared toFrontiers in Oncology | www.frontiersin.org 43DCRT (sHR=3.27 (1.65–6.46) and compared to the general
population (SIR=1.31 (1.06–1.59) whereas for the elderly aged
70–79 years no increased risks were observed (Tables 3, 4,
Figure 2).
Smoking Subgroups
In general, active smoking at time of treatment was significantly
associated with increased SPC risks in the total cohort regardless RT
technique (sHR=1.67 (1.16–2.41) for active smokers vs other
smoking categories). Comparing IMRT with 3DCRT within the
subgroup of active smokers, the sHR for non-pelvic SPC was 2.94
(1.28–6.76), whereas no significant differences between IMRT and
3DCRT were observed for the remaining smoking categories (Table
4, Figure 3). The observed interaction between treatment techniqueTABLE 1 | Baseline Characteristics of the IMRT and 3DCRT PCa patient cohort (N=1,561).
IMRT (n=707) 3DCRT (n=854) p-value
n % n %
Patient
Birth cohort
<1935 99 14.0% 278 32.6% <0.01
1935–1940 281 39.7% 276 32.3%
>1940 327 46.3% 300 35.1%
Age at radiotherapy
50–69 286 40.5% 392 45.9% 0.031
70–79 421 59.5% 462 54.1%
Smoking status at time of RT
Never Smoker 219 31.0% 276 32.3% 0.3
Past Smoker 162 22.9% 190 22.2%
Active Smoker 125 17.7% 150 17.6%
Not Reported 201 28.4% 238 27.9%
Interval diagnosis-RT
1–6 months 617 87% 773 91% <0.01
>6–12 months 33 5% 51 6%
>12 months 57 8% 30 3%
Tumor
Previous cancer diagnosis
No 662 93.6% 798 93.4% 0.9
Yes 45 6.4% 56 6.6%
PCa Risk group
Low-Intermediate 228 32.2% 354 41.5% <0.01
High* 479 67.8% 500 58.5%
Treatment
Adjuvant Hormonal Therapy
Yes 403 57.0% 412 48.2% 0.023
No 304 43.0% 442 51.8%
Calendar Period RT
2006–2009 83 11.7% 673 78.8% <0.01
2010–2012 624 88.3% 181 21.2%
Dose Prostate (P)
72 Gy 16 2.3% 373 43.7% <0.01
78 Gy 691 97.7% 481 56.3%
Dose Seminal Vesicles (SV)
0 Gy 123 17.4% 195 22.8% <0.01
50–78 Gy 584 82.6% 659 77.2&
Image-Guidance
Offline (bony anatomy) 129 18.2% 854 100% <0.01
Online (prostate) 578 81.8% 0 0%
Energy Megavolts (MV)
10 449 63.5% 4 0.5% <0.01
18 258 36.5% 318 37.2%
23 0 0% 532 62.3%November 2020 | Volume 10 | Article*T3 or Gleason >7 or PSA >20 µ/L.605119
Jahreiß et al. Second Cancer After Modern RadiotherapyTABLE 2 | Standardized Incidence Ratios (SIRs) for the total cohort compared to the general Dutch male population, adjusted for age and calendar year.
Second Tumor Site Observed (n) Expected (n) SIR (95% CI)
All solid (excluding skin) 233 254.3 0.92 (0.80–1.04)
All solid non-pelvis 168 140.9 1.19 (1.02–1.39)
Anatomical Regions
Chest 73 62.8 1.16 (0.91–1.46)
Lung & bronchus 49 49.4 0.99 (0.73–1.31)
Abdomen 73 60.7 1.20 (0.94–1.51)
Esophagus 16 8.8 1.82 (1.04–2.95)
Stomach 3 4.9 0.61 (0.13–1.79)
Colon 31 33.2 0.93 (0.63–1.22)
Pancreas 11 7.8 1.41 (0.70–2.52)
Kidney, Renal Pelvis and Ureter 18 11.7 1.54 (0.91–2.43)
Pelvis 70 50.2 1.39 (1.09–1.76)
Bladder & Urethra 50 33.4 1.50 (1.11–1.97)
Rectum & Rectosigmoid 21 15.3 1.37 (0.85–2.10)
Sub-sites
Urinary Tract 68 45.8 1.48 (1.15–1.88)
Gastrointestinal 95 78.1 1.22 (0.98–1.49)
Central Nervous System 5 2.6 1.92 (0.62–4.49)
Unknown 7 5.3 1.32 (0.53–2.72)
Age Groups
Patients aged 50–69 years
All solid SPC 101 77.3 1.31 (1.06–1.59)
All solid SPC non-pelvis 74 54.4 1.36 (1.07–1.71)
Patients aged 70-79 years
All solid SPC 139 122.6 1.13 (0.95–1.34)
All solid SPC non-pelvis 94 86.4 1.09 (0.88–1.33)Frontiers in Oncology | www.frontiersin.org 5 November 2020 | Volume 10Observed and expected reflect number of observed and expected survivors experiencing the SPC event of interest. For SPC sub-sites, all experienced SPCs are taken into consideration. SIR=observed/
expected. Evaluation period is diagnoses + 1 year up to end of exposure (end of observation period is 31-12-2019). Grouping of regions and ICD10 codes is reflected in Supplementary File 1.
Bold numbers represent significantly elevated SIRs (p < 0.05).TABLE 3 | Standardized Incidence Ratios (SIRs) for the IMRT and 3DCRT cohort compared to the general Dutch male population, adjusted for age and calendar year.
Second Tumor Site IMRT (n=697) 3D-CRT (n=851)
Observed (n) Expected (n) SIR (95% CI) Observed (n) Expected (n) SIR (95% CI)
All solid (excluding skin) 101 96.4 1.05 (0.85–1.27) 132 158.1 0.83 (0.70–0.99)
All solid non-pelvis 73 53.4 1.37 (1.07–1.72) 95 87.4 1.09 (0.88–1.33)
Anatomical Regions
Chest 33 23.6 1.40 (0.96–1.96) 40 39.1 1.02 (0.73–1.39)
Lung & bronchus 23 18.4 1.25 (0.79–1.88) 26 30.9 0.84 (0.55–1.23)
Abdomen 24 23.5 1.02 (0.65–1.52) 49 37.2 1.32 (0.97–1.74)
Esophagus 8 3.5 2.29 (0.99–4.50) 8 5.2 1.54 (0.66–3.03)
Stomach 1 1.8 0.56 (0.01–3.10) 2 3.3 0.61 (0.07–2.19)
Colon 9 12.7 0.71 (0.32–1.35) 22 20.5 1.07 (0.67–1.62)
Pancreas 2 2.9 0.69 (0.08–2.49) 9 4.9 1.84 (0.84–3.49)
Kidney, Renal Pelvis and Ureter 8 4.4 1.82 (0.78–3.58) 10 7 1.43 (0.69–2.63)
Pelvis 31 19 1.63 (1.11–2.32) 39 31.2 1.25 (0.89–1.71)
Bladder & Urethra 20 12.5 1.6 (0.98–2.47) 30 21 1.43 (0.96–2.04)
Rectum & Rectosigmoid 12 5.8 2.07 (1.07–3.61) 9 9.4 0.96 (0.44–1.82)
Sub-sites
Urinary Tract 27 17.5 1.54 (1.02–2.24) 41 28.4 1.44 (1.04–1.96)
Gastrointestinal 37 30 1.23 (0.87–1.70) 58 48.2 1.20 (0.91–1.56)
Central Nervous System 4 1 4.00 (1.09–10.24) 1 1.7 0.59 (0.01–3.28)
Unknown 4 1.7 2.35 (0.64–6.02) 3 3.4 0.88 (0.18–2.58)
Age Groups
Patients aged 50–69 years
All solid SPC 48 26.1 1.84 (1.36–2.44) 53 51.6 1.03 (0.77–1.34)
All solid SPC non-pelvis 35 18.4 1.90 (1.32–2.65) 39 36.1 1.08 (0.77–1.48)
Patients aged 70–79 years
All solid SPC 56 50.3 1.11 (0.84–1.45) 83 72.2 1.15 (0.92–1.43)
All solid SPC non-pelvis 38 35.3 1.08 (0.76–1.48) 56 51.3 1.09 (0.82–1.42)Observed and expected reflect number of observed and expected survivors experiencing the SPC event of interest. For SPC sub-sites, all experienced SPCs are taken into consideration. SIR=observed/
expected. Evaluation period is diagnoses + 1 year up to end of exposure (end of observation period is 31-12-2019). Grouping of regions and ICD10 codes is reflected in Supplementary File 1.
Bold numbers represent significantly elevated SIRs (p < 0.05).| Article 605119
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endpoint pelvic SPC, no difference was observed for IMRT vs
3DCT within the active smoker subgroup (sHR=1.79 (0.48–6.70).
Evaluating specific frequent SPC endpoints known to be related to
smoking (lung, bladder), we observed no significant differences
between IMRT and 3DCT. A comparison with the general
population within smoking categories was not possible because
smoking status is not registered in the NCR.
Other SPC Endpoints
Regarding anatomical regions and specific tumor types, most
prominent differences between IMRT and the internal and
external reference populations were found for bladder/urethra,
kidney/renal pelvis/ureter and rectum/rectosigmoid (Tables 3, 4).
Comparing 3DCRT to the general population, only excess cancer
risks (p<0·05) were observed for the genitourinary tract, whereas
for IMRT excess cancer risks (p<0·05) were observed for many
SPC endpoints (Table 4): all solid, non-pelvic pelvic, rectosigmoid,
and genitourinary. For the combined RT cohort, significant excess
risks were observed for the SPC endpoints solid non-pelvis,
esophagus, pelvis, bladder, and urinary Tract, and for the age
subgroup 50–69 years (all solid and non-pelvis) (Table 2).
Excess Absolute Risk (EAR)
Based on the results of the Fine and Gray model, the estimated
EAR for non-pelvic SPC (per 10,000 person-years) for IMRT is
+7 SPC cases (95% CI 1–16) in addition to the baseline risk of 12Frontiers in Oncology | www.frontiersin.org 6cases with 3DCRT. For the age subgroup 50–69 years the
estimated EAR is +19 cases with a quite large confidence
interval (5–46), in addition to the baseline risk of 8 cases with
3DCRT. If we take the ratio of the estimated SIRs for IMRT and
3DCRT as an alternative estimate of the relative SPC risks and
associated AERs, the estimated AERs for non-solid SPC (IMRT
vs 3DCRT) are smaller: +3 cases for IMRT – total group, and +7
for IMRT – 50–69 years.DISCUSSION
To our knowledge, this is the first study evaluating the impact of
IMRTon SPC risks in a large patient populationwith full details on
their treatment for localized PCa, comparing risks to both the
general population and an internal 3DCRT reference group. We
observed a significantly increased risk for the primary endpoint of
non-pelvic SPC, in particular for the subgroups of age 50–69 years
and active smokers. The IMRT population did differ from the
3DCRT population with respect to the prescribed dose level (more
often 78 Gy) and prescription of adjuvant hormonal therapy,
however, at the performed sensitivity analysis we demonstrated
that these factors did not affect our estimates of the main results.
Previously, Journy et al. (15) assessed a large prostate cancer
cohort from the SEER (Surveillance, Epidemiology, and End
Results) registry database, with patients aged >65–<85 years
treated with either IMRT or 3DCRT. For the endpoint of solidTABLE 4 | Crude incidence rates (per 10,000-person years) and estimated subHazard Ratios by Gray and Fine method (with adjustment for age and calendar year at
time of radiotherapy) for IMRT versus the reference group 3DCRT.
Subsite (ICD10 code) IMRT 3DCRT Fine & Gray Model
n with SPC Incidence rate n with SPC Incidence rate sHRs (95% CI) p-value
All solid (except skin) C00–C80 99 20.90 126 13.01 1.23 (0.88–1.76) 0.220
Solid SPC non-pelvis 74 15.62 85 12.27 1.56 (1.03–2.36) 0.034
Age at RT
50–69 years 37 18.93 29 8.49 3.27 (1.65–6.46) 0.001
70–79 years 37 13.29 56 15.96 0.96 (0.59–1.59) 0.887
Smoking Status at RT
Never smoker 17 10.79 24 10.47 0.80 (0.32–1.98) 0.631
Past smoker 21 20.66 30 19.60 0.94 (0.43–2.06) 0.875
Active smoker 25 33.33 15 12.94 2.94 (1.28–6.76) 0.011
Not reported 11 7.88 16 8.22 1.20 (0.42–3.40) 0.734
SPC within anatomical regions
Chest 30 6.33 36 5.20 1.21 (0.65–2.26) 0.548
Abdomen 26 5.48 42 6.06 1.13 (0.59–2.16) 0.719
Pelvis 27 5.70 40 5.77 0.79 (0.41–1.47) 0.437
SPC by tumor site
Urinary tract total 23 4.85 37 5.34 0.72 (0.35–1.49) 0.380
Bladder, urethra 17 3.59 29 4.19 0.56 (0.27–1.18) 0.128
Kidney, renal pelvis, ureter 8 1.69 6 0.87 3.90 (0.64–23.80) 0.140
Gastrointestinal total 34 7.18 53 7.65 1.07 (0.62–1.86) 0.802
Rectum, rectosigmoid 10 2.11 9 1.30 2.41 (0.76–7.64) 0.135
Colon 10 2.11 17 2.45 0.82 (0.31–2.15) 0.688
Oesophagus & Stomach 9 1.90 13 1.88 1.30 (0.41–4.19) 0.655
Pancreas, liver, biliary tract 6 1.27 14 2.02 0.57 (0.20–1.61) 0.287
Lung & Bronchus 21 4.43 24 3.46 1.19 (0.57–2.48) 0.636
Soft tissue/sarcoma 2 0.42 2 0.29 1.20 (0.05–31.84) 0.914November 2020 | Volume 10 | ArticleNumbers reflect observed number of survivors experiencing the SPC event of interest. For SPC sub-sites, only the first SPC is taken into consideration. Grouping of regions and ICD10
codes is reflected in Supplementary File 2.
Bold numbers represent significantly elevated SIRs (p < 0.05).605119
Jahreiß et al. Second Cancer After Modern Radiotherapytumors in5-years survivors, theyobservedno significantdifferences
between IMRT and 3DCRT, which is in rough agreement with our
results for the age group >69 years. Buwenge et al. (16) compared
PCa patients treated with 3DCRT (n=538) to PCa patients treated
with IMRT(n=1988).They reported elevated SPCrisks in the pelvic
region for IMRT treated with nodal irradiation. Since our
population was not subject to nodal irradiation, a valid
comparison to our results is not possible. Zelefsky et al. (17)
studied SPC rates in a PCa population treated with IMRT
(n=897) or brachytherapy (n=413) with a median of 8y follow-
up, comparing SPC risks between themodalities and eachmodality
with the general population, and reported no excess risks in the
IMRT group compared to the general population and the
brachytherapy group for the overall SPC endpoint and for infield
and out of field SPC (excluding skin cancer). For the IMRT vs
brachytherapy comparison, they report a 10y estimated cumulative
SPC incidence of 16 vs 12% (p=0.3) They included no 3DCRT
group for comparison. Furthermore, the brachytherapy group
contained a subgroup treated with both brachytherapy and
additional IMRT to the prostate and seminal vesicles. Xiang et al.Frontiers in Oncology | www.frontiersin.org 7(5) compared SPC rates between IMRT, 3DCRT, and proton
cohorts for various tumor sites with a median follow-up of 5
years, and reported for PCa favorable SPC rates after proton
therapy and no significant impact of IMRT compared to 3DCRT.
In the present study we used data from the general male
population for the calculation of background SPC risks in the
IMRT and 3DCRT cohort which is a broadly applied approach in
SPC research (17–20). An alternative approach often used in
prostate cancer cohorts, is to compare SPC rates between
radiotherapy and other treatment modalities such as surgery (7).
Reported results on elevated SPC risks of these two types of
approaches are roughly in agreement, identifying increased SPC
risk afterPCa radiotherapy for bladder cancerand rectal cancer, and
in some studies also for other types of cancer in or close to the pelvic
area suchas soft tissue carcinomaandcolon cancer (7, 9, 19).Weare
currently working on a separate project, using national cancer
registry data, in which we compare SPC patterns between several
PCa treatment modalities (external beam radiotherapy,
brachytherapy, surgery, active surveillance) for different calendar
periods in order to estimate additional risks of external beamA
B
FIGURE 1 | Cumulative Incidence of solid SPCs for the IMRT and 3DCRT
cohort, as estimated by the Fine and Gray model adjusted for calendar period and
age. (A) For SPCs in the pelvic region. (B) For non-pelvic SPCs (primary
endpoint).A
B
FIGURE 2 | Cumulative Incidence of non-pelvic SPCs for IMRT and 3DCRT
subgroups, as estimated by the Fine and Gray model adjusted for calendar
period and age. (A) PCa survivors aged 50–69 years at time of treatment.
(B) PCa survivors aged 70–79 years at time of treatment.November 2020 | Volume 10 | Article 605119
Jahreiß et al. Second Cancer After Modern Radiotherapyradiotherapy versus other treatment options including possible
time trends related to the introduction of modern radiotherapy.
Age is an important factor for the risk of developing a
radiation-induced cancer, as previously demonstrated in the
atomic bomb Life Span studies, as well as in other cohort studies
on the impact of radiation on cancer risks (3, 21–23). In line with
these observations from epidemiological studies, our study results
showed that relative youngpatients (<69) are at increased risk for a
(radiation-induced) SPC using IMRTwhereas older patients have
no or limited risks. In a recent study of Krasnow et al. (24), excess
SPC risks (bladder, rectum) for different age categories of PCa
cancer survivors were estimated and they reported highestHazard
Ratios (HR) for survivors aged < 65 years at time of treatment (HR
of 1.7), limited risks for age category >75 year (HR of 1.1), and a
HR of about 1.4 for the categories in between. This emphasizes the
importance of distinguishing between the risk older PCa
patients receiving IMRT are exposed to, to that of relatively
younger patients.
In this study we applied a latency period of 1 year. In a cohort
study of Arnold et al. (18), evaluating SPCs after RT in the pelvic
region in females (for cervical cancer), excess risks were evaluated
for different follow-up periods. They observed no excess risks for
0.5–1 years, and they did report excess risks for the periods 1–5
years, 5–10 years, and 10+ years. Several studies showed in
particular an increased risk for radiation-induced SPC for the
period after 10 years of follow-up (9, 10). However, in a PCa
population with most cases aged between 60–80 years, especially
excess SPC risks in the first 10 years are important since they will
have eventually have the most impact on survival rates.Frontiers in Oncology | www.frontiersin.org 8Bladder cancer is the most commonly reported radiation-
induced SPC after RT for PCa. A recent study of Moschini et al.
(25), comparing RT with prostatectomy, showed increased rates
of bladder cancer from 1year follow-up onwards. Wallis et al. (7)
showed that studies with and without a latency period of 5 years
observed similar excess risks for bladder cancer (7). We observed
increased bladder cancer rates compared to the general
population (SIR=1.5 for the combined cohort), with no
differences between IMRT and 3DCRT.
For rectal cancer we observed no increased risks with respect to
the general population in the 3DCRT group whereas for IMRT a
significant increase was observed. Based on literature, for both
groups an increase was expected (26–28). However, Moschini et al.
(25) observed no increased risks for rectal cancer, comparing RT
with prostatectomy in a recent study in 80,000 individuals. Several
studies have demonstrated that the risks for radiation-induced
rectal cancer are in particular present after 10 years of follow-up,
whereas ourmedian follow-up is currently limited to 8 years with a
maximum of 11 years. Furthermore, national screening programs
for colorectal cancer might have had an impact on incidences
especially in the general population reference group.
With respect to the significantly increased non-pelvic SPC risks for
IMRT, we observed several significant results for sub-sites: rectum,
urinary tract, and central nervous system (Table 3). However, to draw
firmconclusionsonelevated risks for specific sub-sitesusing IMRT,we
need a larger study population frommultiple RT centers, whichwe are
aiming for in a next step of our project.
A major limitation of previous cohort studies investigating the
risk of developing SPC in PCa patients is that smoking data are notA B
DC
FIGURE 3 | Cumulative Incidence of non-pelvic SPCs for IMRT and 3DCRT subgroups, as estimated by the Fine and Gray model adjusted for calendar period and
age. (A) Never smokers. (B) Previous smokers at time of treatment. (C) Active smokers at time of treatment. (D) Smoking status not reported in patient files.November 2020 | Volume 10 | Article 605119
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potential bias of smoking cannot be estimated in such studies.
In our study, we were able to assess the impact smoking has on the
risk of developing SPCs by evaluating SPC risks in an IMRT and
3DCRT cohort with known and similar distributions of smoking
status. We observed a significantly increased incidence of SPCs
within the IMRT cohort, compared to the 3DCRT cohort for
active smokers whereas for other smoking categories estimated
risks were modest. Previous studies have indicated that smoking
and RT are interactive factors impacting the risk of developing
SPCs, especially for smoking-related cancer sites and in active
smokers (18, 29). However, this mechanism is expected in both the
3DCRT and IMRT setting. Based on our results, more scatter dose
associated with IMRT combined with active smoking and its
associated presence of mutations in organs (30) might have
caused additional risks. To our knowledge, this increased risk of
SPC in active smokers receiving IMRT has not been reported
before, and joined effects of active smoking and peripheral low
dose exposure with IMRT have not been modeled before. Further
study of this observation is required to draw firm conclusions.
Based on dose measurements and published risk models, several
investigators previously hypothesized that modern radiation
techniques might be associated with increased SPC risks in PCa
survivors (1, 2, 11, 31). A shared view in these studies is that age and
beam-on time are key factors. Hall et al. (1), hypothesized that with
IMRT a total of about 0.75% additional PCa survivors will develop a
SPCcompared toconventionalRT.Kryet al. (2), estimated this riskas
2–3 times higher in aworst case situation of young patients with long
survival. Stathakis et al. (11), calculated that the riskdoubles. Sánchez-
Nieto (31) ranked treatment techniques based on NTCP and SPC
risks and concluded that IMRT was a superior choice and SPC risks
had little impact on the ranking, especially for the elderly.
Furthermore, several authors recommend a photon energy of 10
MVfor IMRTinPCaas thebest trade-off betweenperipheralneutron
exposure (which increases with higher energies) and photon
exposure (which increases with lower energies because of an
increased beam-on time) (2, 32, 33). In our study, IMRT was
delivered with both 10 MV and 18 MV. Our (limited) data did not
show increased SPC risks for the 18 MV subgroup.
The major strengths of the current study is that we collected
detailed RT data as well as smoking data, and compared IMRT to
the general population and an internal 3DCRT reference
population. The study lacked however statistical power
concerning analyses by SPC site specifically and its follow-up is
limited with a maximum of 11 years and median of 8 years.
Furthermore, we have currently not investigated possible links
between estimated dose levels to anatomical sub-sites at risk for
SPC (with IMRT and 3DCRT) and observed SPCs incidences. We
have planned to perform such analyses within larger multi-center
datasets in the future, e.g. within a nested case-control design.
Further research and validation of the current results on modern
radiotherapy and SPC risks is currently ongoing in a project with a
multi-center setting with prolonged follow-up and more detailed
RT characteristics.
In conclusion, IMRT is associated with unfavorable excess
SPC risks in patients treated at a relative young age, and activeFrontiers in Oncology | www.frontiersin.org 9smoking might have an additional negative impact on these risks.
Further study of causal relationships between IMRT aspects and
excess SPC risks in larger multi-center populations is needed
with the goal to keep risks for future patients at a minimum.DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.ETHICS STATEMENT
The studies involving human participants were reviewed and approved
by Medische Ethische Toetsings Commissie (METC), Erasmus MC,
Rotterdam, The Netherlands. Written informed consent for
participation was not required for this study in accordance with the
national legislation and the institutional requirements.AUTHOR CONTRIBUTIONS
WH, MH, KA, and LI contributed to the study design. M-CJ,
WH, KA, MD, and KV contributed to data collection and
analysis. All authors participated in data interpretation. M-CJ,
WH, KA, MD, and MH contributed to writing the manuscript.
WH, KA, MD, and KV contributed to supervision and study
management. All authors contributed to the article and approved
the submitted version.FUNDING
For this project a grant was received from the Dutch Cancer
Society (KWF), nr 12009. The funder of the study is a non-profit
organization and it had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all the data and
had final responsibility for the decision to submit for publication.ACKNOWLEDGMENTS
Wewould like to thank Bo van Santvoort for supporting us with the
data analysis and Yvette van Norden for statistical advice.We would
also like to thank Hadassah Reuvekamp and Maria Ahmadi for
their contribution to data collection and interpretation of the data.
We would like to thank the Dutch Cancer Society (KWF) for
funding this study.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fonc.2020.
605119/full#supplementary-materialNovember 2020 | Volume 10 | Article 605119
Jahreiß et al. Second Cancer After Modern RadiotherapyREFERENCES
1. Hall EJ, Wuu C-S. Radiation-induced second cancers: the impact of 3D-CRT
and IMRT. Int J Radiat Oncol Biol Phys (2003) 56(1):83–8. doi: 10.1016/
s0360-3016(03)00073-7
2. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, et al.
The calculated risk of fatal secondary malignancies from intensity-modulated
radiation therapy. Int J Radiat Oncol Biol Phys (2005) 62(4):1195–203.
doi: 10.1016/j.ijrobp.2005.03.053
3. Grant EJ, Brenner A, Sugiyama H, Sakata R, Sadakane A, Utada M, et al. Solid
Cancer Incidence among the Life Span Study of Atomic Bomb Survivors:
1958-2009. Radiat Res (2017) 187(5):513–37. doi: 10.1667/RR14492.1
4. Piotrowski I, Kulcenty K, Suchorska WM, Skrobała A, Skórska M, Kruszyna-
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